Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Salivary Gland Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Head and Neck Cancer (516
)
Thyroid Gland Carcinoma (344
)
Squamous Cell Carcinoma of Head and Neck (268
)
Nasopharyngeal Carcinoma (52
)
Oral Cancer (51
)
Oropharyngeal Cancer (23
)
Tongue Carcinoma (4
)
Head and Neck Cancer (516
)
Thyroid Gland Carcinoma (344
)
Squamous Cell Carcinoma of Head and Neck (268
)
Nasopharyngeal Carcinoma (52
)
Oral Cancer (51
)
Oropharyngeal Cancer (23
)
Tongue Carcinoma (4
)
›
Associations
(52)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 positive
Salivary Gland Cancer
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
PD-L1 expression
Salivary Gland Cancer
PD-L1 expression
Salivary Gland Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
No biomarker
Salivary Gland Cancer
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
No biomarker
Salivary Gland Cancer
cisplatin + vinorelbine tartrate
Sensitive: A2 - Guideline
cisplatin + vinorelbine tartrate
Sensitive
:
A2
cisplatin + vinorelbine tartrate
Sensitive: A2 - Guideline
cisplatin + vinorelbine tartrate
Sensitive
:
A2
NTRK2 fusion
Salivary Gland Cancer
NTRK2 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Salivary Gland Cancer
NTRK1 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Salivary Gland Cancer
NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Salivary Gland Cancer
NTRK3 fusion
Salivary Gland Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Salivary Gland Cancer
NTRK1 fusion
Salivary Gland Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Salivary Gland Cancer
NTRK2 fusion
Salivary Gland Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
AR positive
Salivary Gland Cancer
AR positive
Salivary Gland Cancer
leuprolide acetate
Sensitive: A2 - Guideline
leuprolide acetate
Sensitive
:
A2
leuprolide acetate
Sensitive: A2 - Guideline
leuprolide acetate
Sensitive
:
A2
AR positive
Salivary Gland Cancer
AR positive
Salivary Gland Cancer
bicalutamide
Sensitive: A2 - Guideline
bicalutamide
Sensitive
:
A2
bicalutamide
Sensitive: A2 - Guideline
bicalutamide
Sensitive
:
A2
RET fusion
Salivary Gland Cancer
RET fusion
Salivary Gland Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
HER-2 positive
Salivary Gland Cancer
HER-2 positive
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
No biomarker
Salivary Gland Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
carboplatin + gemcitabine
Sensitive: A2 - Guideline
carboplatin + gemcitabine
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
No biomarker
Salivary Gland Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
No biomarker
Salivary Gland Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
BRAF V600E
Salivary Gland Cancer
BRAF V600E
Salivary Gland Cancer
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
HER-2 overexpression
Salivary Gland Cancer
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive: C1 - Off-label
trastuzumab
Sensitive
:
C1
trastuzumab
Sensitive: C1 - Off-label
trastuzumab
Sensitive
:
C1
RET fusion
Salivary Gland Cancer
RET fusion
Salivary Gland Cancer
pralsetinib
Sensitive: C1 - Off-label
pralsetinib
Sensitive
:
C1
pralsetinib
Sensitive: C1 - Off-label
pralsetinib
Sensitive
:
C1
HER-2 positive
Salivary Gland Cancer
HER-2 positive
Salivary Gland Cancer
trastuzumab-pkrb
Sensitive: C1 - Off-label
trastuzumab-pkrb
Sensitive
:
C1
trastuzumab-pkrb
Sensitive: C1 - Off-label
trastuzumab-pkrb
Sensitive
:
C1
HER-2 amplification
Salivary Gland Cancer
HER-2 amplification
Salivary Gland Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
ado-trastuzumab emtansine
Sensitive
:
C2
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
ado-trastuzumab emtansine
Sensitive
:
C2
HER-2 overexpression
Salivary Gland Cancer
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
HER-2 amplification
Salivary Gland Cancer
HER-2 amplification
Salivary Gland Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
AR positive
Salivary Gland Cancer
AR positive
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + bicalutamide
Sensitive
:
C3
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + bicalutamide
Sensitive
:
C3
PLIN2 expression
Salivary Gland Cancer
PLIN2 expression
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + bicalutamide
Sensitive
:
C3
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
leuprolide acetate + bicalutamide
Sensitive
:
C3
AKT1 E17K
Salivary Gland Cancer
AKT1 E17K
Salivary Gland Cancer
AZD5363
Sensitive: C3 – Early Trials
AZD5363
Sensitive
:
C3
AZD5363
Sensitive: C3 – Early Trials
AZD5363
Sensitive
:
C3
HER-2 expression
Salivary Gland Cancer
HER-2 expression
Salivary Gland Cancer
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
HRAS mutation
Salivary Gland Cancer
HRAS mutation
Salivary Gland Cancer
tipifarnib
Sensitive: C3 – Early Trials
tipifarnib
Sensitive
:
C3
tipifarnib
Sensitive: C3 – Early Trials
tipifarnib
Sensitive
:
C3
HER-2 amplification
Salivary Gland Cancer
HER-2 amplification
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
HER-2 expression
Salivary Gland Cancer
HER-2 expression
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
PTEN expression
Salivary Gland Cancer
PTEN expression
Salivary Gland Cancer
bicalutamide
Sensitive: C3 – Early Trials
bicalutamide
Sensitive
:
C3
bicalutamide
Sensitive: C3 – Early Trials
bicalutamide
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login